Immunome Statistics
Total Valuation
Immunome has a market cap or net worth of $2.02 billion. The enterprise value is $1.57 billion.
Important Dates
The last earnings date was Monday, November 9, 2026, after market close.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunome has 118.07 million shares outstanding. The number of shares has increased by 37.06% in one year.
| Current Share Class | 118.07M |
| Shares Outstanding | 118.07M |
| Shares Change (YoY) | +37.06% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 1.11% |
| Owned by Institutions (%) | 104.38% |
| Float | 113.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 100.39 |
| PB Ratio | 4.30 |
| P/TBV Ratio | 4.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.66, with a Debt / Equity ratio of 0.03.
| Current Ratio | 11.66 |
| Quick Ratio | 11.34 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -78.71% and return on invested capital (ROIC) is -49.53%.
| Return on Equity (ROE) | -78.71% |
| Return on Assets (ROA) | -45.14% |
| Return on Invested Capital (ROIC) | -49.53% |
| Return on Capital Employed (ROCE) | -62.57% |
| Weighted Average Cost of Capital (WACC) | 18.79% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.06M |
| Employee Count | 267 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.51% in the last 52 weeks. The beta is 2.66, so Immunome's price volatility has been higher than the market average.
| Beta (5Y) | 2.66 |
| 52-Week Price Change | -6.51% |
| 50-Day Moving Average | 20.09 |
| 200-Day Moving Average | 22.08 |
| Relative Strength Index (RSI) | 37.53 |
| Average Volume (20 Days) | 1,417,763 |
Short Selling Information
The latest short interest is 16.17 million, so 13.70% of the outstanding shares have been sold short.
| Short Interest | 16.17M |
| Short Previous Month | 17.28M |
| Short % of Shares Out | 13.70% |
| Short % of Float | 14.29% |
| Short Ratio (days to cover) | 11.77 |
Income Statement
| Revenue | n/a |
| Gross Profit | -226.54M |
| Operating Income | -290.69M |
| Pretax Income | -282.65M |
| Net Income | -282.65M |
| EBITDA | -287.50M |
| EBIT | -290.69M |
| Earnings Per Share (EPS) | -$2.60 |
Full Income Statement Balance Sheet
The company has $461.58 million in cash and $11.39 million in debt, with a net cash position of $450.20 million or $3.81 per share.
| Cash & Cash Equivalents | 461.58M |
| Total Debt | 11.39M |
| Net Cash | 450.20M |
| Net Cash Per Share | $3.81 |
| Equity (Book Value) | 454.30M |
| Book Value Per Share | 4.00 |
| Working Capital | 436.83M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$229.03 million and capital expenditures -$9.67 million, giving a free cash flow of -$238.70 million.
| Operating Cash Flow | -229.03M |
| Capital Expenditures | -9.67M |
| Depreciation & Amortization | 3.19M |
| Net Borrowing | n/a |
| Free Cash Flow | -238.70M |
| FCF Per Share | -$2.02 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunome does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -37.06% |
| Shareholder Yield | -37.06% |
| Earnings Yield | -15.21% |
| FCF Yield | -11.71% |
Analyst Forecast
The average price target for Immunome is $35.13, which is 105.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.13 |
| Price Target Difference | 105.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | 207.94% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Immunome has an Altman Z-Score of 23.91 and a Piotroski F-Score of 2.
| Altman Z-Score | 23.91 |
| Piotroski F-Score | 2 |